Search research articles
Contact Us
Filters
Showing results (161-170 of 225) with videos related to
Page
of 23
Sort By:
Haematologica
|
December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
American Journal of Hematology
|
December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses
Jennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
British Journal of Haematology
|
June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma
Philippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
The New England Journal of Medicine
|
December 8, 2015
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W Roberts, Matthew S Davids, John M Pagel, et al.
Blood Advances
|
March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Reid W Merryman, Natasha Edwin, Robert Redd, et al.
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies
Kadriye Nehir Cosgun, Huda Jumaa, Mark E Robinson, et al.
Nature Cancer
|
January 8, 2026
Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia
Kadriye Nehir Cosgun, Huda Jumaa, Mark E Robinson, et al.
Blood Advances
|
December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Blood Cancer Journal
|
August 29, 2025
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
Christine E Ryan, Inhye E Ahn, Aswin Sekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 225) with videos related to
Sort By:
Page
of 23
Haematologica
|
December 23, 2021
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, et al.
American Journal of Hematology
|
December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses
Jennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
British Journal of Haematology
|
June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma
Philippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
The New England Journal of Medicine
|
December 8, 2015
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W Roberts, Matthew S Davids, John M Pagel, et al.
Blood Advances
|
March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Reid W Merryman, Natasha Edwin, Robert Redd, et al.
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies
Kadriye Nehir Cosgun, Huda Jumaa, Mark E Robinson, et al.
Nature Cancer
|
January 8, 2026
Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia
Kadriye Nehir Cosgun, Huda Jumaa, Mark E Robinson, et al.
Blood Advances
|
December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Blood Cancer Journal
|
August 29, 2025
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
Christine E Ryan, Inhye E Ahn, Aswin Sekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 23